SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance

Niederer, F.; Ospelt, C.; Brentano, F.; Hottiger, M.O.; Gay, R.E.; Gay, S.; Detmar, M.; Kyburz, D.

Published in: Annals of the Rheumatic Diseases

DOI: 10.1136/ard.2010.148957

Citation for published version (APA):
SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance

Fabienne Niederer,1 Caroline Ospelt,1,2 Fabia Brentano,1 Michael O Hottiger,3 Renate E Gay,1,4 Steffen Gay,1,4 Michael Detmar,5 Diego Kyburz1,4

ABSTRACT

Objective To analyse the expression of SIRT1 in synovial tissues and cells of patients with rheumatoid arthritis (RA) and to study the function of SIRT1 in inflammation and apoptosis in RA.

Methods Levels of SIRT1 expression were analysed in synovial tissues and cells from patients with RA by real-time PCR and western blotting before and after stimulation with toll-like receptor ligands, tumour necrosis factor α (TNFα) and interleukin 1β (IL-1β). Immunohistochemistry was used to study the localisation of SIRT1. Fluorescence activated cell sorting analysis was performed to investigate the effect of SIRT1 on apoptosis. Peripheral blood monocytes and rheumatoid arthritis synovial fibroblasts (RASFs) were transfected with wild-type or enzymatically inactive SIRT1 expression vectors or with siRNA targeting SIRT1. Cytokine analysis of IL-6, IL-8 and TNFα were performed by ELISA to study the role of SIRT1 on proinflammatory mediators of RA.

Results SIRT1 was found to be constitutively upregulated in synovial tissues and cells from patients with RA compared to osteoarthritis. TNFα stimulation of RASFs and monocytes resulted in further induced expression levels of SIRT1. Silencing of SIRT1 promoted apoptosis in RASFs, whereas SIRT1 overexpression protected cells from apoptosis. Inhibition of SIRT1 enzymatic activity by inhibitors, siRNA and overexpression of an enzymatically inactive form of SIRT1 reduced lipopolysaccharide-induced levels of TNFα in monocytes. Similarly, knockdown of SIRT1 resulted in a reduction of proinflammatory IL-6 and IL-8 in RASFs.

Conclusion The TNFα-induced overexpression of SIRT1 in RA synovial cells contributes to chronic inflammation by promoting proinflammatory cytokine production and inhibiting apoptosis.

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by the destruction of joint cartilage and bone. Synovial hyperplasia and persistent synovial inflammation with infiltration of inflammatory immune cells into the synovial lining are hallmarks of RA.1 Innate immunity was shown to be important for the development of chronic arthritis. Activation of toll-like receptors (TLRs) and NOD-like receptors in synovial cells leads to the expression of several proinflammatory genes, such as interleukin 6 (IL-6) and tumour necrosis factor α (TNFα).2,3 We have previously reported the induction of the adipokine PBEF (pre-B cell colony enhancing factor), also called visfatin, upon stimulation of TLRs.4 PBEF/Visfatin catalyses the rate-limiting step in the biosynthesis of nicotinamide-adenine-dinucleotide (NAD+).5 By regulating intracellular NAD+ levels, PBEF/visfatin influences the activity of a variety of NAD+ consuming enzymes, including the sirtuins (SIRT).6,7

SIRTs are a conserved family of NAD+ dependent histone deacetylases and mono-ADP-ribosyltransferases that target histones, transcription factors and coregulators to adapt gene expression to the cellular energy state.8–10 In mammals seven sirtuin genes—SIRT1 to SIRT7—have been identified. Among them, SIRT1 is best characterised so far and has been shown to regulate transcription factors such as p53,11 members of the forkhead transcription factor FOXO family,12 the DNA repair factor Ku70,13 nuclear factor-κB (NF-κB)14 and the transcriptional coactivator p300.15

In lung cancer cell lines, SIRT1 was found to physically interact with, and deacetylate, the RelA/p65 subunit of NF-κB, thereby inhibiting its ability to interact with promoter regions of target genes to enhance transcription.14 Hyperacetylation of lysine 310 of RelA/p65 rendered NF-κB highly active, resulting in increased transcription of proinflammatory cytokines such as TNFα and IL-1 in a myeloid SIRT1 knockout mouse model.16 However, nicotinamide has been shown to reduce the production of proinflammatory cytokines as well as IL-10 in primary human macrophages, possibly by inhibiting sirtuins.17

In recent years, SIRT1 has gained much attention since its expression was shown to mediate longevity.18 SIRT1 deacetylates the DNA repair factor Ku70 leading to inhibition of apoptosis. In addition, SIRT1 protected epithelial cells from p53-mediated apoptosis.11,19 In contrast to these findings, in HEK293 epithelial cells, SIRT1 augmented apoptosis in response to TNFα,14 highlighting the possibility that SIRT1 may have different biological outcomes depending on the apoptotic stimuli.

So far, SIRT1 expression and function in the RA synovium has not been analysed. Therefore, in view of the controversial results on the influence of sirtuins on inflammation and apoptosis, we analysed the expression, regulation and function of SIRT1 in RA. We showed overexpression of SIRT1 in synovial tissues from patients with RA. In addition, SIRT1 is shown to decrease apoptosis in synovial cells and to promote proinflammatory cytokine production.
MATERIAL AND METHODS

Patients and tissue preparation

Synovial tissue biopsy specimens were obtained from patients with RA and osteoarthritis (OA), after informed consent had been obtained (Department of Orthopedic Surgery, Schulthess Clinic, Zurich, Switzerland). All patients with RA fulfilled the American College of Rheumatology criteria for classification of RA. Synovial tissue specimens were digested and synovial fibroblasts (SFs) were grown as previously described. The patient characteristics used in this study are shown in table 1.

Preparation of monocytes from peripheral blood

Isolation of peripheral blood mononuclear cells from the whole blood of healthy donors or patients with RA was performed using standard ficoll density-gradient centrifugation (GE Healthcare, Otelingsingen, Switzerland). Monocytes were separated by positive selection with CD14 MACS MicroBeads or, when used for stimulation or transfection experiments, by negative selection with MACS MicroBeads Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany).

Stimulation assays

Rheumatoid arthritis synovial fibroblasts (RASFs) and primary peripheral monocytes from healthy individuals were plated in 12- and 24-well plates (5x10⁴ and 3–5x10⁵ cells/well) in 500 μl supplemented Dulbecco's modified Eagle's medium and RPMI, respectively, and stimulated for the indicated time points with the following agents: 300 ng/ml Pam3CSK4, 10 μg/ml poly(I:C) (both from InvivoGen, San Diego, California, USA), 10 ng/ml lipopolysaccharide (LPS from Escherichia coli J5; List Biologicals, Campbell, California, USA), 10 ng/ml TNFα, 1 ng/ml IL-1β (both from R&D Systems, Abingdon, UK), 30 μM Sirtinol (Sigma, Buchs, Switzerland) or 9 μM EX-527 (Tocris Bioscience, St. Louis, Missouri, USA), 10 ng/ml TNFα, 10 ng/ml IL-β (both from R&D Systems, Abingdon, UK), 30 μM Sirtinol (Sigma, Buchs, Switzerland) or 9 μM EX-527 (Tocris Bioscience, St. Louis, UK).

Transfection experiments

Monocytes from healthy volunteers and RASFs were transfected using AMAXA nucleofection kits VPA-1007 and VVIH-1002 (both from Lonza, Cologne, Germany), respectively. For silencing experiments, 100 μg SIRT1 wild-type, SIRT1 mutant (H363Y), empty pcDNA3.1(-) (mock) or no nucleic acid (untransfected) was used. pcDNA3.1-SIRT1-MYC/His wild-type and the catalytically inactive mutant (H363Y) have been described previously. Transfected monocytes were further incubated at 37°C for 18–20 h before stimulation with LPS for 8 h, in presence or absence of 50 μM sc-514 (Sigma). RASFs were transfected for 48 h and subsequently stimulated with LPS or TNFα for 24 h (siRNA) or 40 h (vectors). Successful transfection was confirmed by real-time PCR using SIRT1 mRNA-specific primers.

Real-time PCR

Total RNA was isolated with the RNase-free DNase (Qiagen, Hombrechtikon, Switzerland) and reverse transcribed using random hexamers and multiprimer reverse transcriptase (both from Applied Biosystems, Rotkreuz, Switzerland). Non-reverse transcribed samples were used as negative controls. Quantification of SIRT1 and IL-6 mRNA was performed by TaqMan RT-PCR using the ABI Prism 7700 Sequence Detection system (Applied Biosystems). The primer sequences are shown in table 2. The endogenous control 18S rRNA was used for correcting the results with the comparative threshold cycle method for relative quantification as described by the manufacturer.

ELISA

Protein in cell supernatants was detected by ELISA with OptEIA Kits (BD Pharmingen, San Diego, California, USA) for TNFα, IL-6 and IL-8 according to the manufacturer's instructions. Absorption was measured at 450 nm and data were analysed using Revelation v.4.22 software (Dynex Technologies, Denkendorf, Germany).

Immunohistochemistry

Synovial tissues were fixed in paraformaldehyde and embedded in paraffin. Tissue sections were deparaffinised and pretreated with 10 mM citrate buffer, pH 6. After blocking endogenous peroxidase and non-specific binding, slides were incubated with rabbit IgG (Jackson, Suffolk, UK) or rabbit-anti-human SIRT1 antibody (E104, 1:40; Abcam, Cambridge, UK) overnight at 4°C. For double staining, 2 μg/ml mouse-anti-vimentin, mouse-anti-CD68 antibodies (both from Dako, Glostrup, Denmark) or mouse IgG (Jackson) were added. Sections were incubated with biotinylated goat-anti-rabbit IgG and AP-conjugated goat-anti-mouse antibodies (both from Dako, Glostrup, Denmark) or rabbit-anti-human SIRT1 antibody (Jackson, Cambridge, UK). SIRT1-positive cells were visualised using DAB-Nickel (Vector Laboratories, Peterborough, UK). SIRT1-positive cells were visualised using Vector Red reagent. SIRT1 single stained and IgG control slides were counterstained with eosin.

Immunoblotting

For protein preparation, tissues and cells were lysed in RIPA buffer, boiled and mixed with Laemmli buffer. Proteins were separated on sodium dodecyl sulphate (SDS)-polyacrylamide gels and transferred to nitrocellulose membranes (Schleicher and Schüll, Dassel, Germany). Membranes were probed with anti-SIRT1

---

**Table 1** Characteristics of the study patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Patients with RA (n=39)</th>
<th>Patients with OA (n=10)</th>
<th>Healthy controls (n=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years, mean (range))</td>
<td>62 (29–86)</td>
<td>76 (64–98)</td>
<td>43 (29–64)</td>
</tr>
<tr>
<td>Sex (n (female/male))</td>
<td>31/8</td>
<td>5/5</td>
<td>4/2</td>
</tr>
<tr>
<td>Disease duration (years, mean (range))</td>
<td>25 (3–50)</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

Medications (n (taking/assessed))

| NSAIDs | 12/39 | 3/10 | 0/6 |
| DMARDs | 31/39 | 0/10 | 0/6 |
| RF+ (>20 IU) | 28/29 | NA | NA |

CRP (mg/l, mean (range))

| 14.4 (1.0–52.5) | 6.9 (0.9–39.5) | NA |

* Patients with OA were significantly older than patients with RA and healthy controls. † Healthy controls were significantly younger than patients with OA and RA. CRP C-reactive protein; DMARDs, disease-modifying antirheumatic drugs; NA, not assessed; NSAIDs, non-steroidal anti-inflammatory drugs; OA, osteoarthritis; RA, rheumatoid arthritis; RF, rheumatoid factor.

**Table 2** SYBR green primers used for real-time PCR

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIRT1 forward</td>
<td>5′-GCG GGA ATC CAA AGG ATA AT-3′</td>
</tr>
<tr>
<td>SIRT1 reverse</td>
<td>5′-CGT TGG CAA AAC AGG AAC CAT GA-3′</td>
</tr>
<tr>
<td>IL-6 forward</td>
<td>5′-CTC TTC TGA ACG AAT TGA CAA ACA A-3′</td>
</tr>
<tr>
<td>IL-6 reverse</td>
<td>5′-GAG ATG CCG TCG AGG ATG TAC-3′</td>
</tr>
</tbody>
</table>

IL-6, interleukin 6.
antibodies (E104; Abcam) and anti-α-tubulin (Sigma), respectively, and detected with horseradish peroxidase-conjugated secondary antibodies using the ECL western blotting detection system (Amersham Pharmacia Biotech, Piscataway, New Jersey, USA).

**Fluorescence activated cell sorting**

RASFs were transfected with siRNA or vectors as described above for 48 h. Medium was changed and 24 h later, cells were detached with Accutase (PAA Laboratories, Pasching, Austria) and stained for annexin V and propidium iodide (PI) with the annexin V-FLUOS Staining Kit (Roche, Mannheim, Germany). Cells were subsequently analysed on a FACSCalibur flow cytometer. Data were processed using CellQuest software (BD Biosciences, San Jose, California, USA).

**Statistical analysis**

Unpaired and paired t tests or one-way analysis of variance followed by Dunnett’s post-test were used, where appropriate, for statistical evaluation of the data by GraphPad Prism 5.0 software.

Values are presented as mean (SEM). p values <0.05 were considered as significant.

**RESULTS**

**Elevated expression of SIRT1 in RA synovial tissues**

To study the association of SIRT1 expression with chronic joint inflammation in RA, we compared SIRT1 protein levels in RA with non-inflammatory OA synovial tissues. Western blot analysis revealed higher expression of SIRT1 protein in whole synovial tissue and cultured SFs from joints of patients with RA compared with OA (figure 1A). Real-time PCR analysis showed 5.2-fold higher levels of SIRT1 mRNA in SFs from RA compared with patients with OA (p<0.01). Additionally, levels of SIRT1 mRNA were 2.2 times higher in peripheral blood monocytes from patients with RA compared with healthy volunteers (p<0.01; figure 1B).

**Localisation of SIRT1 expression in RA synovial tissue sections**

To further analyse the expression of SIRT1 in synovial tissue sections from patients with RA, we performed

![Figure 1](https://example.com/figure1.png)

**Figure 1** High basal protein and mRNA levels of SIRT1 in tissues, synovial fibroblasts and monocytes from patients with rheumatoid arthritis (RA). (A) Western blot showing the basal expression of SIRT1 protein from patients with RA and osteoarthritis (OA) in synovial tissue samples (n=4, each) or in synovial fibroblasts (SFs; n=3, each). α-Tubulin served as loading control. (B) Relative expression units of SIRT1 mRNA in synovial fibroblasts from patients with RA (n=7) or OA (n=4) and in monocytes from patients with RA (n=7) or healthy controls (n=6). Results are presented as the difference in threshold cycle (∆Ct), relative to 18S rRNA. See table 1 for patient characteristics. *p<0.01, unpaired t test.

![Figure 2](https://example.com/figure2.png)

**Figure 2** SIRT1 expression in synovial tissues from patients with rheumatoid arthritis (RA). (A) Representative sections of RA synovial tissue specimens stained for SIRT1 or IgG control. Positive staining of SIRT1 appears as dark grey. Sections were counterstained with eosin. (B) Representative sections of RA synovial tissue specimens double-labelled for SIRT1 and vimentin or IgG control. SIRT1 appears as dark grey, and vimentin as red. (C) Representative sections of RA synovial tissue specimens double-labelled for SIRT1 and CD68 or IgG control. SIRT1 appears as dark grey, and CD68 as red. One representative section is shown (n=4). Original magnification ×400.
immunohistochemistry. Pronounced expression of nuclear SIRT1 protein was found in the lining and sublining layers, but also in perivascular areas (figure 2A). Double staining with SIRT1 and vimentin or CD68 showed the expression of SIRT1 in vimentin-positive SFs as well as in CD68-positive monocytes/macrophages (figure 2B, C).

**SIRT1 expression is induced upon stimulation with TNFα**

To analyse the influence of activated TLR pathways and IL-1β on SIRT1 expression, RASFs were treated with TLR ligands and IL-1β for 24 h. Real-time PCR analysis showed no changes in the levels of SIRT1 mRNA. However, stimulation of RASFs with TNFα revealed a modest induction of SIRT1 mRNA (figure 3A). Time course analysis showed increased levels of SIRT1 mRNA already after 1 and 4 h upon stimulation with TNFα (online supplementary figure 1). Western blot analysis of TNFα-stimulated RASFs confirmed induction of SIRT1 protein expression after 48 h (figure 3B). Similarly to RASFs, activation of monocytes by TNFα resulted in a 4.8-fold increase of SIRT1 mRNA levels after 4 h of stimulation (p<0.05), whereas at 24 h SIRT1 mRNA levels had returned to the baseline level (figure 3C).

**SIRT1 mediates apoptosis resistance in RASF**

As SIRT1 has been shown to prolong cellular lifespan and as spontaneous apoptosis is known to be reduced in activated RASFs, we assessed the effect of SIRT1 on apoptotic cell death. RASFs were transfected with siRNA and expression vectors as described above. SIRT1-silenced RASFs showed an increase of 48% and 41% in the number of annexin V-positive (p<0.02) and PI-positive (p<0.03) cells, respectively. When RASFs were transfected to overexpress a vector encoding SIRT1, cells were less susceptible to apoptosis, displayed by a decrease in annexin V-positive (49%, p<0.05) and PI-positive (46%, p<0.05) RASFs (figure 4). These results suggest that the constitutive overexpression of SIRT1 in RASFs may lead to a prolonged lifespan of these cells.

**SIRT1 positively affects production of the proinflammatory mediators IL-6 and IL-8 in RASFs**

We next assessed whether SIRT1 also has a direct impact on the inflammatory phenotype of RASFs. Therefore, the production of the proinflammatory cytokine IL-6 was analysed in LPS-stimulated RASFs after transfection with a SIRT1 expression vector. Interestingly, overexpression of SIRT1 increased the production of LPS-induced IL-6 compared with mock transfected RASFs by 56% (p<0.05). This enhancing effect on IL-6 production was not seen when cells were transfected with a mutant form of SIRT1 (H363Y, figure 5A). Similar results were obtained by stimulation with TNFα instead of LPS (online supplementary figure 2). Analysis of SIRT1 mRNA levels revealed successful overexpression in both wild-type and mutant SIRT1-transfected RASFs (p<0.05, online supplementary figure 3A).

Accordingly, when RASFs were transfected with control or SIRT1 specific siRNA for 48 h, there was a significant reduction of both basal and LPS-stimulated expression of IL-6 and IL-8 after knockdown of SIRT1. Basal IL-6 and IL-8 production was reduced by 37±11% and 47±21% (p<0.05), respectively, whereas...
LPS induced IL-6 and IL-8 levels were reduced by 40±15% and 70±14% (p<0.05), respectively (figure 5B). Also, IL-6 and IL-8 mRNA levels were reduced after SIRT1 knockdown, arguing against purely translational effects of SIRT1 (online supplementary figure 4). Successful knockdown of SIRT1 was confirmed by real-time PCR (online supplementary figure 3B).

**SIRT1 increases production of TNFα in monocytes**

As monocytes produce only small amounts of IL-6, we measured the production of TNFα, a major cytokine involved in the pathogenesis of RA. Freshly isolated monocytes were subjected to transfection with SIRT1 expression vectors or siRNA as described above and subsequently stimulated with LPS. Consistent with the results obtained in RASFs, monocytes overexpressing wild-type SIRT1 showed an increase of 36% in TNFα production compared with mock transfected cells (p<0.01). This induction in TNFα levels was not seen when monocytes were transfected with the mutant form of SIRT1 (H363Y, figure 5C). Non-stimulated cells did not produce detectable amounts of TNFα. Further confirmation that SIRT1 signalling regulates the LPS-induced production of TNFα in monocytes was obtained by specific downregulation of SIRT1 using siRNA. Measurement of LPS-induced TNFα in the cell culture supernatants indicated a significant decrease of 31% (p<0.02) (figure 5D). Real-time PCR analysis was used to verify successful transfections (p<0.02, online supplementary figure 5C, D).

**Enzymatic sirtuin inhibitors decrease TNFα production in monocytes**

As we found a prominent difference in the levels of TNFα between wild-type and mutant SIRT1-transfected monocytes, we tested the effects of commercially available SIRT inhibitors on TNFα production. Monocytes were stimulated with LPS in the presence of the SIRT1-specific enzymatic inhibitor EX-527 and levels of TNFα were measured. Consistent with our previous results, EX-527 reduced the expression of TNFα by 37±17% (p<0.01, figure 6A). Furthermore, we used the pan
sirtuin inhibitor Sirtinol to block the activity of all the sirtuins. Interestingly, Sirtinol also reduced the LPS-induced TNFα production by 49±9% (p<0.01), suggesting that the sirtuin family overall has proinflammatory effects in monocytes (figure 6B).

**The proinflammatory activity of SIRT1 is mediated through NF-κB dependent pathways**

NF-κB is known to be essential for cytokine signalling in RA. Additionally, SIRT1 was shown to affect expression of NF-κB-dependent genes, such as p53 and Bcl-2. We assessed whether the effects of SIRT1 in monocytes are dependent on NF-κB by using an inhibitor of IKK-2, sc-514. When SIRT1 was overexpressed in monocytes, LPS-induced TNFα levels were increased as shown before. This SIRT1-dependent increase was completely blocked by treatment with the IKK-2 inhibitor sc-514, suggesting that SIRT1 acts via a NF-κB dependent mechanism (figure 7).

**DISCUSSION**

SIRT1, a member of the NAD+ dependent class III histone deacetylases, deacetylates both histones and non-histone targets. Thereby, SIRT1 controls a broad range of cellular processes, including cell survival and inflammation. Interestingly, SIRT1 was shown to be induced by calorie restriction (CR), thereby connecting SIRT1 with the beneficial effects of CR on longevity and age-related disorders such as diabetes. In addition, increased levels of SIRT1 were found in diseases such as neurodegeneration, cancer and experimental autoimmune encephalomyelitis. We have analysed SIRT1 expression and found SIRT1 to be overexpressed in RA synovial tissues as compared with OA. SIRT1 is expressed in SFs and monocytes/macrophages, suggesting that in joints SIRT1 is predominantly expressed in tissue resident cells.

The regulation of SIRT1 expression is incompletely understood. Different effects of cytokines on SIRT1 expression have been described. Both the cytokines IL-1β and interferonγ have been shown to reduce the expression of SIRT1 in rat islets, whereas TNFα induced SIRT1 expression in human vascular smooth muscle cells. Here we show that the basal overexpression of SIRT1 in RA can be further induced upon stimulation with TNFα, a major cytokine found in joints of patients with RA. However, SIRT1 expression was not influenced by stimulation with TLR ligands and IL-1β in vitro, suggesting that TLR pathways do not directly regulate SIRT1 expression.

SIRT1 has emerged as a key antiageing protein in different experimental models, such as in *Saccharomyces cerevisiae*, in sirt1-null mice as well as in various in vitro cell cultures. RASFs characteristically show a resistance to apoptosis. We have analysed the effect of SIRT1 on apoptosis in RASFs.
We found that overexpression of SIRT1 protected cells from apoptosis. The antiapoptotic effect of SIRT1 together with its constitutive high expression levels in RA suggest that SIRT1 may contribute to the apoptosis-resistant phenotype seen in RASFs.

Up to now, published data on the effects of SIRT1 on inflammation are controversial. Macrophages from myeloid SIRT1 knockout mice displayed increased NF-kB-mediated inflammation in response to environmental stress, indicating an anti-inflammatory activity of SIRT1. In agreement, a sirtuin activator had an inhibitory effect on LPS-induced inflammation in intraperitoneal murine macrophages. However, the biological effects mediated by SIRT1 seem to differ between cell types. It has been shown that the beneficial effects of CR-induced SIRT1 in white adipose tissue or skeletal muscle cells were not seen in liver tissues.

A previous report using RA synovial biopsy explants showed that treatment with nicotinamide, a non-specific inhibitor of sirtuins, resulted in a reduction of IL-6 and TNFα secretion, suggesting that the sirtuin family may have proinflammatory effects. In line with this finding, it was recently reported that the proinflammatory cytokine HMGB1 stimulated production of TNFα through activation of TLR4 in periodontal cells. This TLR4-dependent enhanced expression of TNFα was blocked when SIRT1 or NF-kB were inhibited. As we have previously shown that TLR activation results in upregulation of NAD+ producing PBEF/visfatin and as SIRT1 activity is NAD+ dependent, it is conceivable that TLR4 stimulation of NAD+ producing PBEF/visfatin, a new master of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 2007;56:2829–39.

This work was supported by the Swiss National Fund grant 32 -120702 (to DK), by FP7 Masterswitch and IAR Epalinges (to CO, REG, SG).

REFERENCES


Extended report

Funding This work was supported by the Swiss National Fund grant 32 -120702 (to DK), by FP7 Masterswitch and IAR Epalinges (to CD, REG, SG).

Competing interests None.

Ethics approval This study was conducted with the approval of the ethics committee of the canton of Zürich.

Provenance and peer review Not commissioned; externally peer reviewed.


SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance

Fabienne Niederer, Caroline Ospelt, Fabia Brentano, et al.

Ann Rheum Dis 2011 70: 1866-1873 originally published online July 8, 2011
doi: 10.1136/ard.2010.148957

Updated information and services can be found at:
http://ard.bmj.com/content/70/10/1866.full.html

These include:
"Web Only Data"
http://ard.bmj.com/content/suppl/2011/06/23/ard.2010.148957.DC1.html

References
This article cites 41 articles, 21 of which can be accessed free at:
http://ard.bmj.com/content/70/10/1866.full.html#ref-list-1

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Immunology (including allergy) (3650 articles)
- Inflammation (797 articles)
- Connective tissue disease (3084 articles)
- Degenerative joint disease (3337 articles)
- Musculoskeletal syndromes (3583 articles)
- Rheumatoid arthritis (2204 articles)
- Osteoarthritis (662 articles)

Notes
To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/